Lorad Medical Systems and Fischer Imaging wielded charges andcountercharges last week during pretrial procedures for Fischer'sstereotactic-guided biopsy patent infringement suit (SCAN 4/8/92). Lorad fired the first public shot with release of a
Lorad Medical Systems and Fischer Imaging wielded charges andcountercharges last week during pretrial procedures for Fischer'sstereotactic-guided biopsy patent infringement suit (SCAN 4/8/92).
Lorad fired the first public shot with release of a statementthat Fischer Imaging has dropped two more of its patent claimsfiled against Lorad. Only two claims remain, down from the 16originally filed in April, Lorad said.
Withdrawing its patent claims one at a time is a way of droppingthe suit while saving face, according to Lorad.
"It's only a matter of time before this case is dismissed,"said Hal Kirshner, Lorad president.
Fischer countered with its own public statement discountingthe importance of the reduced number of claims. Narrowing thenumber of claims is common practice in patent suits as informationis reviewed during the discovery period, said Robert A. Cascella,executive vice president and CFO of Fischer.
Fischer initially cited five interrelated claims against Loradin its suit and reduced this to the two primary claims after reviewingLorad technical documentation, he said. These two claims, regardingelements of prone positioning, the stereotactic guided arm anddigital processing, had always been the essence of the patents,he said.
Lorad has made other claims about Fischer's image quality thatare not substantiated by comparative testing of the two systems,according to the Fischer statement. The company is consideringadditional nonpatent litigation against Lorad related to theseproduct claims, the company said.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.